S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
NASDAQ:MEIP

MEI Pharma - MEIP Competitors

$0.23
-0.01 (-4.22%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.22
$0.24
50-Day Range
$0.21
$0.35
52-Week Range
$0.20
$0.70
Volume
342,018 shs
Average Volume
1.65 million shs
Market Capitalization
$30.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

MEIP vs. LPTX, UNCY, PTN, CRVS, VTGN, ORGS, ELDN, YMTX, TXMD, and CKPT

Should you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Leap Therapeutics (LPTX), Unicycive Therapeutics (UNCY), Palatin Technologies (PTN), Corvus Pharmaceuticals (CRVS), VistaGen Therapeutics (VTGN), Orgenesis (ORGS), Eledon Pharmaceuticals (ELDN), Yumanity Therapeutics (YMTX), TherapeuticsMD (TXMD), and Checkpoint Therapeutics (CKPT). These companies are all part of the "pharmaceutical preparations" industry.

MEI Pharma vs.

MEI Pharma (NASDAQ:MEIP) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

MEI Pharma received 85 more outperform votes than Leap Therapeutics when rated by MarketBeat users. However, 68.52% of users gave Leap Therapeutics an outperform vote while only 64.67% of users gave MEI Pharma an outperform vote.

CompanyUnderperformOutperform
MEI PharmaOutperform Votes
368
64.67%
Underperform Votes
201
35.33%
Leap TherapeuticsOutperform Votes
283
68.52%
Underperform Votes
130
31.48%

Leap Therapeutics has a net margin of 0.00% compared to MEI Pharma's net margin of -49.80%. Leap Therapeutics' return on equity of -65.01% beat MEI Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
MEI Pharma -49.80% -88.33% -26.61%
Leap Therapeutics N/A -65.01% -58.03%

In the previous week, Leap Therapeutics had 5 more articles in the media than MEI Pharma. MarketBeat recorded 9 mentions for Leap Therapeutics and 4 mentions for MEI Pharma. MEI Pharma's average media sentiment score of 0.22 beat Leap Therapeutics' score of 0.03 indicating that MEI Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MEI Pharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Leap Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MEI Pharma has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.

35.7% of MEI Pharma shares are owned by institutional investors. Comparatively, 37.4% of Leap Therapeutics shares are owned by institutional investors. 6.2% of MEI Pharma shares are owned by insiders. Comparatively, 12.5% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MEI Pharma has higher revenue and earnings than Leap Therapeutics. MEI Pharma is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MEI Pharma$40.70 million0.74-$54.45 million-$0.23-0.99
Leap Therapeutics$1.50 million20.46-$54.60 million-$0.48-0.65

MEI Pharma presently has a consensus target price of $3.00, indicating a potential upside of 1,220.42%. Leap Therapeutics has a consensus target price of $2.80, indicating a potential upside of 803.23%. Given MEI Pharma's higher possible upside, equities analysts plainly believe MEI Pharma is more favorable than Leap Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MEI Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Leap Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Leap Therapeutics beats MEI Pharma on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MEIP vs. The Competition

MetricMEI PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$31.98M$5.64B$4.37B$5.82B
Dividend YieldN/A2.62%2.41%4.53%
P/E Ratio-0.997.28131.7714.23
Price / Sales0.74280.743,490.0565.83
Price / CashN/A18.0119.6422.47
Price / Book0.584.214.515.04
Net Income-$54.45M$187.34M$115.19M$191.52M
7 Day Performance-9.16%-0.09%0.42%0.27%
1 Month Performance2.25%-9.55%-7.23%-6.46%
1 Year Performance-60.36%-12.85%-16.00%-19.00%

MEI Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LPTX
Leap Therapeutics
1.8557 of 5 stars
$0.34
flat
$2.80
+735.8%
-81.9%$33.17M$1.50M-0.7136Earnings Report
Short Interest ↑
Analyst Revision
Gap Up
UNCY
Unicycive Therapeutics
2.0309 of 5 stars
$2.20
-2.2%
$6.33
+187.9%
+22.9%$33.11MN/A-2.161Upcoming Earnings
Short Interest ↑
PTN
Palatin Technologies
1.4688 of 5 stars
$3.03
+5.2%
$50.00
+1,550.2%
+531.0%$33.79M$2.88M-0.98N/A
CRVS
Corvus Pharmaceuticals
2.3163 of 5 stars
$0.70
+2.9%
$3.00
+325.6%
-59.2%$32.81MN/A-0.8028Analyst Report
Short Interest ↑
News Coverage
VTGN
VistaGen Therapeutics
1.0417 of 5 stars
$0.16
+14.7%
N/A-88.0%$34.15M$1.11M-0.5031Analyst Revision
Gap Up
High Trading Volume
ORGS
Orgenesis
1.357 of 5 stars
$1.34
-6.3%
N/A-63.2%$34.24M$35.50M-2.53111Short Interest ↓
ELDN
Eledon Pharmaceuticals
2.3842 of 5 stars
$2.50
+8.2%
$22.00
+780.0%
-41.5%$34.40MN/A-0.9412News Coverage
Gap Down
YMTX
Yumanity Therapeutics
0 of 5 stars
$3.18
+0.3%
N/A+86.5%$34.52M$4.84M-1.0640Gap Up
TXMD
TherapeuticsMD
1.4267 of 5 stars
$3.40
-3.4%
N/A-83.0%$32.03M$86.95M-2.38416Upcoming Earnings
Gap Down
CKPT
Checkpoint Therapeutics
2.0227 of 5 stars
$3.77
-1.3%
$23.50
+523.3%
+122.1%$35.06M$270,000.00-0.4314Short Interest ↑
This page (NASDAQ:MEIP) was last updated on 3/29/2023 by MarketBeat.com Staff